Cumberland Pharmaceuticals (CPIX) Non-Current Debt (2010 - 2026)

Cumberland Pharmaceuticals has disclosed Non-Current Debt across 16 years of filings, most recently posting $5.2 million for Q1 2026.

• Non-Current Debt for Q1 2026 came in at $5.2 million, changed 0.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.2 million (changed 0.0% YoY), and the FY2025 annual result was $5.2 million, down 48.5% from the prior year.
• Non-Current Debt came in at $5.2 million for Q1 2026 at Cumberland Pharmaceuticals, roughly flat from $5.2 million in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $20.0 million in Q1 2022 to a low of $5.2 million in Q1 2025.
• The 5-year median for Non-Current Debt is $12.9 million (2023), against an average of $12.1 million.
• Across the five-year window, Non-Current Debt surged 35.71% in 2022 and tumbled 67.43% in 2025, its largest moves.
• Cumberland Pharmaceuticals' Non-Current Debt stood at $16.2 million in 2022, then dropped by 21.09% to $12.8 million in 2023, then slipped by 20.4% to $10.2 million in 2024, then tumbled by 48.5% to $5.2 million in 2025, then changed by 0.0% to $5.2 million in 2026.
• The last three Non-Current Debt figures came in at $5.2 million (Q1 2026), $5.2 million (Q4 2025), and $5.2 million (Q3 2025), per Business Quant data.